DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: BRIUMVI (ublituximab)
       *****************************************************
       #Post#: 4920--------------------------------------------------
       Briumvi sales doing well
       By: agate Date: September 7, 2025, 1:17 am
       ---------------------------------------------------------
       This board doesn't usually feature financial reports but it may
       be of interest that:
       [font=Arial][/font][quote][font=Arial][/font]
       [font=Arial][/size][TG Therapeutics'] primary revenue driver,
       BRIUMVI, is rapidly establishing itself as a commercial success
       story. TG Therapeutics reported total second-quarter 2025
       revenue of $141.1 million, with U.S. sales of BRIUMVI
       contributing $138.8 million to this figure. This represents a
       substantial 91 percent year-over-year increase, highlighting the
       therapy's accelerating market adoption for multiple sclerosis
       treatment.[/font]
       [font=Arial][/size][/font]
       [font=Arial][/size]In response to this powerful sales
       trajectory, management has significantly raised its full-year
       2025 guidance. Instead of previous projections, TG Therapeutics
       now anticipates approximately $570 to $575 million in U.S.
       BRIUMVI revenue alone—a strong indicator of continued robust
       demand.[/font]
       [font=Arial][/size][/font][/quote][font=Arial][/font]
       ktiencheck.de/news/Artikel-TG_Therapeutics_Stock_Riding_a_Wave_o
       f_Commercial_Success-18985749
  HTML https://msspeaks.createaforum.com/ktiencheck.de/news/Artikel-TG_Therapeutics_Stock_Riding_a_Wave_of_Commercial_Success-18985749
       *****************************************************